ES2179208T3 - Derivados hidrofobos de taxano que favorecen la hidrolisis. - Google Patents

Derivados hidrofobos de taxano que favorecen la hidrolisis.

Info

Publication number
ES2179208T3
ES2179208T3 ES96930847T ES96930847T ES2179208T3 ES 2179208 T3 ES2179208 T3 ES 2179208T3 ES 96930847 T ES96930847 T ES 96930847T ES 96930847 T ES96930847 T ES 96930847T ES 2179208 T3 ES2179208 T3 ES 2179208T3
Authority
ES
Spain
Prior art keywords
taxan
hydrolysis
hydrocarbon
hydrophobe
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96930847T
Other languages
English (en)
Inventor
Eric Mayhew
Shaukat Ali
Andrew S Janoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2179208T3 publication Critical patent/ES2179208T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A UN TAXANO QUE PRESENTA UN HIDROCARBURO UNIDO A LAS POSICIONES 2'' Y/O 7, ESTANDO OCUPADA LA POSICION ALFA DEL HIDROCARBURO POR UN "GRUPO PROMOTOR DE HIDROLISIS" ("HPG"). LA SUSTITUCION DE UN HPG POR LA UNIDAD DE METILENO QUE OCUPA NORMALMENTE LA POSICION ALFA, PERMITE UNA HIDROLISIS IN VIVO MEJORADA DEL ENLACE HIDROCARBURO - TAXANO Y, POR TANTO, PERMITE UNA ACTIVIDAD TERAPEUTICA DE TAXANO MEJORADA. ASIMISMO, SE PROPORCIONAN COMPOSICIONES QUE CONTIENEN TAXANO Y METODOS DE ADMINISTRACION DE TAXANOS A ANIMALES, INCLUYENDO AQUELLOS AFECTADOS DE CANCERES.
ES96930847T 1995-09-12 1996-09-12 Derivados hidrofobos de taxano que favorecen la hidrolisis. Expired - Lifetime ES2179208T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US357595P 1995-09-12 1995-09-12

Publications (1)

Publication Number Publication Date
ES2179208T3 true ES2179208T3 (es) 2003-01-16

Family

ID=21706522

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96930847T Expired - Lifetime ES2179208T3 (es) 1995-09-12 1996-09-12 Derivados hidrofobos de taxano que favorecen la hidrolisis.
ES02008590T Expired - Lifetime ES2252347T3 (es) 1995-09-12 1996-09-12 Hidrolisis que promueve derivados hidrofobos de taxano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02008590T Expired - Lifetime ES2252347T3 (es) 1995-09-12 1996-09-12 Hidrolisis que promueve derivados hidrofobos de taxano.

Country Status (22)

Country Link
US (1) US5703117A (es)
EP (1) EP0902783B1 (es)
JP (1) JP4192208B2 (es)
KR (1) KR100401220B1 (es)
CN (1) CN1100770C (es)
AT (2) ATE216377T1 (es)
CA (1) CA2231750C (es)
CZ (1) CZ288562B6 (es)
DE (2) DE69620802T2 (es)
DK (2) DK0902783T3 (es)
ES (2) ES2179208T3 (es)
HK (1) HK1016169A1 (es)
HU (1) HU226325B1 (es)
IL (1) IL123595A (es)
MX (1) MX9801871A (es)
NO (1) NO319521B1 (es)
NZ (1) NZ318300A (es)
PL (1) PL187738B1 (es)
PT (1) PT902783E (es)
SK (1) SK283199B6 (es)
TR (1) TR199800443T1 (es)
WO (1) WO1997010234A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US5912264A (en) * 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
BR9814857A (pt) * 1997-11-10 2001-12-26 Sloan Kettering Inst Cancer Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
IL139541A0 (en) * 1998-05-20 2004-02-08 Liposome Co Inc Novel particulate formulations
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
DE60004630T2 (de) * 1999-01-12 2004-06-17 Quanam Medical Corp., Santa Clara Arzneimittel und verfahren zur verabreichung von wasserunlöslichen paclitaxelderivaten
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US6607689B1 (en) * 2000-08-29 2003-08-19 Micron Technology, Inc. Layer thickness control for stereolithography utilizing variable liquid elevation and laser focal length
DE60137229D1 (de) * 2001-10-22 2009-02-12 Viroblock Sa Non-phospholipid Vesikel (npLV) und ihre Verwendung in kosmetischen, therapeutischen und prophylaktischen Anwendungen
EP1461056A4 (en) * 2001-11-26 2006-01-25 Supergen Inc PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLATED CICRIC OIL IN PHARMACEUTICAL COMPOSITIONS
EP1553924B1 (en) * 2002-06-26 2010-12-08 MediGene AG Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
MXPA05008284A (es) 2003-02-03 2006-03-21 Neopharm Inc Taxano y otros farmacos antineoplasicos encapsulados, liposomicos, estables, susceptibles de esterilizacion por filtracion.
CN104667355A (zh) * 2005-02-18 2015-06-03 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
KR20080009196A (ko) * 2005-04-12 2008-01-25 위스콘신 얼럼나이 리서어치 화운데이션 중합체 및 패신저 약물의 마이셀 조성물
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) * 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
WO2011038278A2 (en) 2009-09-25 2011-03-31 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
CN105503844A (zh) * 2015-12-11 2016-04-20 上海大学 C-13和c-7位结构改造的紫杉醇类化合物及其制备方法
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
KR100378612B1 (ko) * 1992-12-23 2003-04-03 브리스톨-마이어스스퀴브컴파니 신규 측쇄-함유 탁산 및 그의 중간체 화합물
IL108316A (en) * 1993-01-15 2006-10-31 Univ Florida State History of C-10 Texan and pharmaceuticals containing them
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives

Also Published As

Publication number Publication date
WO1997010234A1 (en) 1997-03-20
CZ71198A3 (cs) 1998-07-15
NZ318300A (en) 1999-08-30
SK33498A3 (en) 1998-08-05
KR19990044409A (ko) 1999-06-25
PT902783E (pt) 2002-09-30
IL123595A0 (en) 1998-10-30
DE69620802D1 (de) 2002-05-23
JP4192208B2 (ja) 2008-12-10
DE69620802T2 (de) 2002-10-10
ATE309235T1 (de) 2005-11-15
AU6975696A (en) 1997-04-01
HUP9901433A2 (hu) 2001-04-28
NO981071L (no) 1998-05-12
ES2252347T3 (es) 2006-05-16
CZ288562B6 (cs) 2001-07-11
PL187738B1 (pl) 2004-09-30
SK283199B6 (sk) 2003-03-04
DK0902783T3 (da) 2002-07-22
DE69635428T2 (de) 2006-06-14
ATE216377T1 (de) 2002-05-15
TR199800443T1 (xx) 1998-06-22
PL325477A1 (en) 1998-07-20
IL123595A (en) 2000-10-31
US5703117A (en) 1997-12-30
CA2231750C (en) 2006-07-11
JP2001519755A (ja) 2001-10-23
MX9801871A (es) 1998-05-31
AU706290B2 (en) 1999-06-10
CA2231750A1 (en) 1997-03-20
HK1016169A1 (en) 1999-10-29
HU226325B1 (en) 2008-08-28
NO319521B1 (no) 2005-08-22
EP0902783A4 (es) 1999-03-24
KR100401220B1 (ko) 2004-03-20
EP0902783B1 (en) 2002-04-17
DK1229030T3 (da) 2006-02-13
DE69635428D1 (de) 2005-12-15
CN1100770C (zh) 2003-02-05
HUP9901433A3 (en) 2001-05-28
EP0902783A1 (en) 1999-03-24
CN1202166A (zh) 1998-12-16
NO981071D0 (no) 1998-03-11

Similar Documents

Publication Publication Date Title
ES2179208T3 (es) Derivados hidrofobos de taxano que favorecen la hidrolisis.
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
CR6392A (es) Moduladores de ccr5
DE69716135T2 (de) In 6-position durch thio substituierte paclitaxele
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
BR0014767A (pt) Fibras de sementes de plantas e uso
ES2136725T3 (es) Utilizacion de 2-amino-6-n-propil-amino-4,5,6,7-tetrahidrobenzotiazol (pramipexol) como medicamento con efecto antidepresivo.
IT1317102B1 (it) Ago del tipo da biopsia o per altri prelievi da organi umani o dianimali.
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
IT1244886B (it) Dicarbonati e uretani dell'acido 4,5-diidrossi- e 4,5,8-triidrossi- 9,10-diidro-9,10-diosso-2-antracencarbossilico ad azione terapeutica
TR26421A (tr) Aminosilikon islah edici madde ihtiva eden elyaf islah edici terkipler.
ES2066914T3 (es) Factores a1, a2, a3 y h del antibiotico ge 2270.
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
DE68927055D1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
PT86771A (pt) Process for preparing 4-substituted benzamide derivatives with anticonvulsant activity
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
SE8500822D0 (sv) Diazepinoindoles, their production and pharmaceutical compositions containing them
ATE75619T1 (de) Bestaendige therapeutische zusammensetzungen, basierend auf hydrophobem pflanzlichem oel und verfahren zu ihrer herstellung.
PT1351680E (pt) Utilizacao de anetole-ditioletiona na prevencao e tratamento da tenotoxicidade induzida por um medicamento
ES2161361T3 (es) N-oxidos como agentes antibacterianos.
IT8919498A0 (it) Derivati del 3,4 deidro piperidin 5 one ad attivita' erbicida.
BR9812869A (pt) Processo para a preparação de benzofuranonas eventualmente substituìdas
AR004380A1 (es) Dihidrato del (2r-3s)-3-ter-butoxicarbonilamino-2-hidroxi-3-fenilpropionato de 4,10 beta-diacetoxi-2 alfa, -benzoiloxi-5beta, 20-epoxi -1-hidroxi-9-oxo-19-norciclopropa [g]tax-11-eno-13alfa-ilo y su procedimiento de preparacion.
ECSP993296A (es) Moduladores de ccr5